2023
DOI: 10.1016/j.carrev.2023.03.006
|View full text |Cite
|
Sign up to set email alerts
|

Application of Impella Mechanical Circulatory Support Devices in Transcatheter Aortic Valve Replacement and Balloon Aortic Valvuloplasty: A Single-Center Experience

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 21 publications
0
2
0
Order By: Relevance
“…In an analysis by Almajed et al, regarding emergent TAVI and BAV in a population consisting of 120 patients (26 TAVI, 94 BAV, 53.9% CS), in specific for etiology analysis, Impella-TAVI in CS patients had a 30-day mortality rate of 34.6%, while Impella-BAV had a 30-day mortality rate of 44.2%. In these cases, Impella was used prior to the procedure in order to achieve hemodynamic stability [ 40 ]. Similar high mortality rates (40%) in patients requiring Impella have been reported by Almalla et al [ 41 ], with low device-associated complications.…”
Section: Urgent Transcatheter Interventions For Aortic Pathologiesmentioning
confidence: 99%
“…In an analysis by Almajed et al, regarding emergent TAVI and BAV in a population consisting of 120 patients (26 TAVI, 94 BAV, 53.9% CS), in specific for etiology analysis, Impella-TAVI in CS patients had a 30-day mortality rate of 34.6%, while Impella-BAV had a 30-day mortality rate of 44.2%. In these cases, Impella was used prior to the procedure in order to achieve hemodynamic stability [ 40 ]. Similar high mortality rates (40%) in patients requiring Impella have been reported by Almalla et al [ 41 ], with low device-associated complications.…”
Section: Urgent Transcatheter Interventions For Aortic Pathologiesmentioning
confidence: 99%
“…In the past decade, the management of severe acute heart failure (AHF) has been significantly transformed by the introduction of percutaneously implanted mechanical circulatory support (MCS) devices [ 1 ]. These MCS devices, inserted via a catheter, play a crucial role in temporarily maintaining blood flow during high-risk procedures, such as percutaneous coronary intervention (PCI), transcatheter aortic valve replacement (TAVR), and balloon aortic valvuloplasty (BAV), especially in cases involving cardiogenic shock and severe left ventricle (LV) dysfunction [ 2 , 3 ]. They act as a bridge to recovery (or bridge to decision), facilitating blood flow to vital organs while alleviating strain on the recovering myocardium and allowing the LV to rest.…”
Section: Introductionmentioning
confidence: 99%